IMPACT OF GENETICS ON NEOADJUVANT THERAPY
WITH COMPLETE PATHOLOGICAL RESPONSE
IN METASTATIC COLORECTAL CANCER:
CASE REPORT AND REVIEW OF THE LITERATURE
Bulajic P1, Bidzic N1,*, Djordjevic V1, Ceranic M1,2, Basaric D1,2, Pesic V3, Djordjevic-Pesic J4
*Corresponding Author: Nemanja Bidzic, M.D., Clinic for Digestive Surgery, Clinical Center of
Serbia, Koste Todorovica 6, Belgrade 11000, Serbia. Tel. +381-11-306-5957. Fax: +381-11-306-5967.
E-mail: nemanja bidzic@yahoo.com
page: 75
|
|
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers
C, Rebelo M, et al. Cancer incidence and mortality
worldwide: Sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-
E386.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y,
Kornprat P, Gonen M, et al. Actual 10-year survival
after resection of colorectal liver metastases defines
cure. J Clin Oncol. 2007; 25(29): 4575-4580.
3. André T, Boni C, Mounedji-Boudiaf L, Navarro M,
Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil,
and leucovorin as adjuvant treatment for colon cancer.
N Engl J Med. 2004; 350(23): 2343-2351.
4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart
LH. Clinical score for predicting recurrence after
hepatic resection for metastatic colorectal cancer:
Analysis of 1001 consecutive cases. Ann Surg. 1999;
230(3): 309-318.
5. Nordlinger B, Sorbye H, Glimelius B, Poston GJ,
Schlag PM, Rougier P, et al. Perioperative chemotherapy
with FOLFOX4 and surgery versus surgery
alone for resectable liver metastases from colorectal
cancer (EORTC 40983): A randomised, controlled
trial. Lancet. 2008; 37(9617): 1007-11016.
6. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud
F, Schuch G, Zubel A, et al. Efficacy according to
biomarker status of cetuximab plus FOLFOX-4 as
first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 2011; 22(7): 1535-
1546.
7. Saltz LB, Clarke S, Díaz-Rubio E, Scheithaure W,
Figer A, Wong R, et al. Bevacizumab in combination
with oxaliplatin-based chemotherapy as first-line
therapy in metastatic colorectal cancer: A randomized
phase III study. J Clin Oncol. 2008; 26(12): 2013-
2019.
8. Gruenberger B, Tamandl D, Schueller J, Scheithauer
W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine,
and oxaliplatin as neoadjuvant therapy for patients
with potentially curable metastatic colorectal
cancer. J Clin Oncol. 2008; 26(11):1830-1835.
9. Manne U, Jadhav T, Putcha BK, Samuel T, Soni S,
Shanmugam C, et al. Molecular biomarkers of colorectal
cancer and cancer xisparities: Current status
and perspective. Curr Colorectal Cancer Rep. 2016;
12(6): 332-344.
10. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD,
Andres A, Audard V, et al. Importance of histological
tumor response assessment in predicting the outcome
in patients with colorectal liver metastases treated
with neo-adjuvant chemotherapy followed by liver
surgery. Ann Oncol. 2007; 18(2): 299-304.
11. Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F,
Paule B, et al. Complete pathologic response after
preoperative chemotherapy; myth or reality? J Clin
Oncol. 2008, 26(10): 1635-1641.
12. Nordlinger B, Sorbye H, Glimelius B, Poston GJ,
Schlag PM, Rougier P, et al. Perioperative FOLFOX4
chemotherapy and surgery versus surgery alone for
resectable liver metastases from colorectal cancer
(EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):
1208-1215.
13. Chua TC, Saxena A, Liauw W, Kokandi A, Morris
DL. Systematic review of randomized and nonrandomized
trials of the clinical response and outcomes
of neoadjuvant systemic chemotherapy for resectable
colorectal liver metastases. Ann Surg Oncol. 2010;
17(2): 492-501.
14. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay
D, Castaing D, et al. Five-year survival following
hepatic resection after neoadjuvant therapy for nonresectable
colorectal [liver] metastases. Ann Surg
Oncol. 2001; 8(4): 347-353.
15. Small RM, Lubezky N, Shmueli E, Figer A, Aderka
D, Nakache R, et al. Response to chemotherapy predicts
survival following resection of hepatic colorectal
metastases in patients treated with neoadjuvant
therapy. J Surg Oncol. 2009; 99(2): 93-98.
16. Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada
Y, Takahashi K, et al. A multicenter phase II trial
of mFOLFOX6 plus bevacizumab to treat liver-only
metastases of colorectal cancer that are unsuitable for
upfront resection (TRICC0808). Ann Surg Oncol.
2015; 22(3): 908-915.
17. Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger
B, Kaczirek K, et al. Bevacizumab improves
pathological response of colorectal cancer liver me tastases treated with XELOX/FOLFOX. Ann Surg
Oncol. 2010; 17(8): 2059-2065.
18. Ayez N, Lalmahomed ZS, van der Pool AE, Vergouwe
Y, van Montfort K, de Jonge J, et al. Is the clinical risk
score for patients with colorectal liver metastases still
useable in the era of effective neoadjuvant chemotherapy?
Ann Surg Oncol. 2011; 18(10): 2757-2763.
19. Schreckenbach T, Malkomes P, Bechstein WO,
Woeste G, Schnitzbauer AA, Ulrich F. The clinical
relevance of the Fong and the Nordlinger scores in
the era of effective neoadjuvant chemotherapy for
colorectal liver metastasis. Surg Today. 2015; 45(12):
1527-1534.
20. Balachandran VP, Arora A, Gonen M, Ito H, Turcotte
S, Shia J, et al. A validated prognostic multigene
expression assay for overall survival in resected colorectal
cancer liver metastases. Clin Cancer Res. 2016;
22(10): 2575-2582.
21. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis
F, Bafaloukos D, Kosmidis P, et al. Assessment of
somatic k-RAS mutations as a mechanism associated
with resistance to EGFR-targeted agents: a systematic
review and meta-analysis of studies in advanced
non-small-cell lung cancer and metastatic colorectal
cancer. Lancet Oncol. 2008; 9(10): 962-972.
22. Schirripa M, Loupakis F, Lonardi S, Cremolini C,
Bergamo F, Zagonel V, et al. Phase II study of singleagent
cetuximab in KRAS G13D mutant metastatic
colorectal cancer. Ann Oncol. 2015; 26(12): 2503-
2503.
23. Yokota T, Sano T, Shimizu Y, Takahari D, Senda Y,
Shimura M, et al. Pathological complete response of
colorectal liver metastases following chemotherapy
with S-1 and oxaliplatin (SOX) in combination with
bevacizumab: A case report. Oncol Lett. 2011; 2(2):
201-205.
24. Arata R, Itamoto T, Ikeda S, Nakahara H, Oshita A,
Shinozaki K, et al. Pathological complete response
after neoadjuvant chemotherapy for rectal cancer with
synchronous multiple liver metastases: a report of an
unusual case. Surg Case Rep. 2016; 2(1): 106.
25. Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi
S, Luppi G, et al. Complete pathological response
in a patient with multiple liver metastases from colon
cancer treated with Folfox-6 chemotherapy plus
bevacizumab: a case report. J Hematol Oncol. 2009;
2: 35.
26. Naiken SP, Toso C, Rubbia-Brandt L, Thomopoulos
T, Roth A, Mentha G, et al. Complete path-ological
response (ypT0N0M0) after preoperative chemotherapy
alone for stage IV rectal cancer. BMC Surg.
2014; 14: 4.
27. Bujko K, Nowacki MP, Nasierowska-Guttmejer A,
Michalski W, Bebenek M, Kryj M. Long-term results
of a randomised trial comparing preoperative shortcourse
radiotherapy with preoperative conventionally
fractionated chemoradiation for rectal cancer. Br J
Surg. 2006; 93(10): 1215-1223.
28. Van Vledder MG, Pawlik TM, Munireddy S, Hamper
U, De Jong MC, Choti MA. Factors determining
the sensitivity of intraoperative ultrasonography in
detecting colorectal liver metastases in the modern
era. Ann Surg Oncol. 2010; 17(10):2756-2763.
29. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM,
Kopetz S, Palavecino M, et al. Association of computed
tomography morphologic criteria with pathologic
response and survival in patients treated with
bevacizumab for colorectal liver metastases. JAMA.
2009; 302(21): 2338-2344.
|
|
|
|
 |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
